In addition, according to the recent molecular-pathological profiling studies for advanced EGFR mutation-positive non-small cell lung cancer at baseline, the coexisting multiple genetic, phenotypic, and functional mechanisms may contribute to disease progression and cause intrinsic TKI resistance [46]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.